Humanin

Plain-English version: humanin is a very small protein (a "peptide") that your body already makes inside its mitochondria — the tiny structures in every cell that generate energy. What surprised scientists is where its instructions live: not in the nuclear DNA that codes most of our proteins, but inside the mitochondria's own small genome, in a stretch of the 16S ribosomal RNA gene.

Humanin was identified in 2001 by Hashimoto and colleagues, who were screening for factors that could rescue neurons from death caused by Alzheimer's-related genes and by amyloid-beta (the protein that clumps in Alzheimer's brains). The peptide they found abolished that neuronal death in cultured cells — and it turned out to be encoded in mitochondrial DNA.^[1] That made humanin the founding member of a new family called mitochondrial-derived peptides (MDPs), which now also includes MOTS-c and the SHLP peptides.

Why this was a big deal: mitochondria were long thought of as simple "power plants." The discovery that they also release signaling peptides — chemical messages that tell the rest of the cell to survive or to adjust its metabolism — reframed them as active communicators. Researchers call this "retrograde signaling," meaning the message travels backward from the mitochondria out to the cell.

Native humanin vs. HNG: most laboratory work does not use the natural peptide. It uses a lab-made analog called HNG (S14G-humanin), in which a single amino acid at position 14 is swapped (serine to glycine). Across this literature HNG is described as dramatically more potent than native humanin — a figure of roughly 1,000-fold is commonly cited — which is why most in-vivo rodent studies use HNG. This matters for anyone reading dosing claims: native humanin and HNG are not interchangeable.

The credibility caveat, up front: humanin is not approved for any medical use, has no completed Phase 1 human safety trial, and holds no compounding or bulk-substance status with the FDA. It is strictly a preclinical research compound; anything sold online is unregulated, and there is no legal pathway for human therapeutic use in the U.S. For the wider legal picture, see Are Peptides Legal?

Takeaway first: humanin's clearest, best-supported job is to stop cells from committing suicide. Cells have a built-in self-destruct program called apoptosis, and humanin blocks a key trigger of it. Beyond that anchor mechanism, humanin also nudges metabolic and survival signaling, though those pathways are less fully mapped. Here is what the verified research actually shows.

1. Blocking Bax — the core anti-apoptotic mechanism (best-supported)

Apoptosis is programmed cell death: a controlled way for the body to remove damaged cells. A protein called Bax is one of its main executioners — when activated, Bax moves from the cell's cytosol to the mitochondria and punches holes in the mitochondrial membrane, which commits the cell to die. Guo and colleagues showed that humanin directly binds Bax and prevents it from translocating to the mitochondria, stopping that fatal membrane permeabilization. When they used siRNA to lower a cell's own humanin, the cells became more vulnerable to Bax-driven death.^[2] Evidence level: biochemical and cell-culture experiments — not humans.

This is the mechanism that explains humanin's original discovery: by keeping Bax in check, humanin protected neurons from a wide spectrum of familial Alzheimer's mutations (in the APP, presenilin-1, and presenilin-2 genes) and from amyloid-beta, all in cultured neuronal cells.^[1]

2. Metabolic signaling through the brain (hypothalamic STAT3)

Humanin also acts as a metabolic messenger. In rats, Muzumdar and colleagues infused humanin directly into the brain's ventricles (an "intracerebroventricular," or ICV, infusion) and saw whole-body insulin sensitivity improve — meaning the body needed less insulin to manage blood sugar. The effect ran through STAT3 signaling in the hypothalamus: when they co-blocked STAT3, the benefit disappeared. Potent humanin derivatives given into the bloodstream reproduced the insulin-sensitizing effect peripherally.^[3] Evidence level: rats. This links a mitochondrial peptide to the brain's control of body-wide metabolism, but it has not been demonstrated in humans.

3. Other proposed pathways (less settled)

The broader humanin literature describes additional players — a cell-surface receptor complex (often written as FPRL1/FPRL2) and an interaction with insulin-like growth factor binding protein 3 (IGFBP-3) — as routes for humanin's survival and metabolic effects. These are part of the mechanistic story researchers have built, but they sit on less verified ground than the Bax and STAT3 findings above, so treat them as plausible pieces rather than settled facts.

What we do NOT know

There is no established human pharmacokinetics for exogenous humanin (how an injected dose is absorbed, distributed, and cleared in people), no confirmed human dose-response, and no proof that any of these animal mechanisms translate into a human benefit. Mechanism in a dish or a mouse is a lead, not a result.

How to read this section: for each area we give the plain-English claim, the proposed mechanism, the population actually studied, the observed effect, and the limitation. Almost every finding below is from cells or rodents. The one place with any human data — cognition — is correlational, not a trial. None of this is proof of a human benefit.

Neuroprotection (the original discovery)

Claim: may protect neurons from Alzheimer's-related damage. Mechanism: Bax inhibition and anti-apoptotic signaling. Population: cultured neuronal cells. Effect: humanin abolished neuronal death caused by a wide spectrum of familial Alzheimer's genes and by amyloid-beta.^[1] Limitation: this is a cell-culture finding — not a whole animal and certainly not a human. It tells us humanin is neuroprotective in a dish, nothing more.

Cognition and aging

Claim: may support cognition as we age. Mechanism: cytoprotection of neurons. Population: aged mice (given humanin) plus a large human cohort (observed, not dosed). Effect: Yen and colleagues reported that humanin administration improved cognition in aged mice and was neuroprotective in human cell culture; separately, they found that a natural genetic variant (the SNP rs2854128) which lowers circulating humanin was associated with accelerated cognitive aging in an independent group of older adults.^[4] Limitation — read this carefully: the human part is an association. No humanin was ever given to those people. It suggests that having naturally higher humanin tracks with a "younger" cognitive age, but it cannot show that injecting humanin would do anything. The efficacy evidence is the mouse data.

Insulin sensitivity and metabolism

Claim: may improve how the body responds to insulin. Mechanism: hypothalamic STAT3 signaling with peripheral metabolic effects. Population: rats. Effect: continuous ICV humanin infusion significantly improved whole-body insulin sensitivity, an effect abolished when STAT3 was co-inhibited; intravenous infusion of potent HN derivatives reproduced the insulin-sensitizing effect in the periphery.^[3] Limitation: rodent model only; no human glucose or diabetes data exist. These effects position humanin alongside MOTS-c as a mitochondrial metabolic regulator, but that comparison is mechanistic, not clinical.

Cardioprotection

Claim: may reduce heart damage during a heart attack. Mechanism: anti-apoptotic protection of heart-muscle cells during reperfusion injury. Population: mice subjected to 45 minutes of coronary artery occlusion followed by 24 hours of reperfusion. Effect: the analog HNG, given into the abdomen (intraperitoneally), reduced myocardial infarct size relative to the area at risk in a dose-dependent way, with the maximal reduction at 2 mg/kg.^[5] Limitation: a single acute-injury mouse model — and that "2 mg/kg" is a mouse dose, not a human dose. It is the clearest published dosing figure in the humanin literature precisely because most work reports no clean number at all.

Aging biology (review context)

Claim: falling mitochondrial-peptide levels may contribute to aging. Mechanism: loss of protective retrograde signaling. Population: narrative review of the field. Effect: Kim and colleagues argue that declining levels of mitochondrial-derived peptides, including humanin, are linked to cellular senescence, chronic inflammation, and cognitive decline in aging.^[7] Limitation: this is a review — useful for framing the hypothesis, not primary evidence for any specific effect size. It should not be read as proof that supplementing humanin reverses aging.

The honest bottom line on "benefits"

• No human clinical trials have been completed. No interventional trial of exogenous humanin (or HNG) has ever given the peptide to people. Human pharmacokinetics, effective doses, and outcomes are unknown.
• The only human data are correlational. Lower natural humanin tracks with faster cognitive aging — an association, not a demonstrated treatment effect.^[4]
• Findings are preclinical and, in the neuroprotection case, in-vitro only. A result in a dish is a starting point, not a conclusion.
• Anecdotes are not data. Online reports of benefit cannot substitute for controlled trials that do not yet exist.

Read this first: there is no clinically validated human dose for humanin, because no human dosing trial has ever been done. The clearest published dose in the entire literature is a mouse figure — HNG at 2 mg/kg intraperitoneally, the point of maximal cardioprotection in a mouse heart-attack model.^[5] The milligram-per-day human protocols circulating online are extrapolations from animal work, not trial-derived doses. We describe them below for completeness and harm reduction, not as medical guidance or a recommendation to self-administer an unapproved compound.

Native humanin vs. HNG — why the numbers differ so much

Before any number makes sense, you have to know which compound you have. The synthetic analog HNG (S14G-humanin) is described in the literature as roughly 1,000 times more potent than native humanin because of a single amino-acid substitution at position 14. Most material sold as "humanin" is actually HNG. Dosing the two as if they were equivalent would be a serious error — always verify the form on the Certificate of Analysis before anything else.

Commonly cited research protocols (extrapolated, not validated)

Purpose	Compound	Commonly cited dose	Route	Frequency
Cytoprotection (low)	HNG	0.5-1 mg	Subcutaneous	Once daily
General anti-aging	HNG	1-2 mg	Subcutaneous	Once daily
Metabolic support	HNG	1-3 mg	Subcutaneous	Once daily
Native humanin	Humanin (HN)	5-10 mg	Subcutaneous	Once daily

Every figure in that table is a community extrapolation, not a validated human dose. They exist because people wanted a starting point, not because a trial produced them. Treat them as unverified.

Route in plain terms

Humanin is a 24-amino-acid peptide with negligible oral bioavailability — swallowed, it is broken down by digestive enzymes before it can reach the bloodstream — so subcutaneous injection is the route people use. Many of the original animal studies used intraperitoneal (into the abdomen) injection, which is a laboratory route, not something used in human self-administration; the human SC estimates are back-calculated from those animal doses using allometric (body-size) scaling, a rough approximation at best.

Reconstitution math, with a worked example

Humanin (usually HNG) ships as a lyophilized (freeze-dried) powder that must be mixed with bacteriostatic water before use. The core formula:

Concentration (mg/mL) = vial amount (mg) ÷ water added (mL)

Worked example: take a 5 mg vial and add 2 mL of bacteriostatic water. That gives 5 ÷ 2 = 2.5 mg/mL, i.e. 2,500 mcg per mL. To draw a 1 mg (1,000 mcg) dose: 1,000 ÷ 2,500 = 0.40 mL, which is 40 units on a standard 100-unit insulin syringe. A 2 mg dose is 0.80 mL, or 80 units.

Vial	BAC water	Concentration	1 mg dose	2 mg dose
5 mg	2 mL	2.5 mg/mL	0.40 mL (40 units)	0.80 mL (80 units)
5 mg	1 mL	5.0 mg/mL	0.20 mL (20 units)	0.40 mL (40 units)
10 mg	2 mL	5.0 mg/mL	0.20 mL (20 units)	0.40 mL (40 units)

Preparation steps: wipe the vial stopper with alcohol; draw the water; inject it slowly down the inside wall of the vial rather than blasting the powder; swirl gently (do not shake) until fully dissolved; label the vial with the date and concentration. Use the peptide calculator to check volumes and the reconstitution guide for a full walkthrough.

Cycle length and timing (convention, not trial-derived)

• Cycle: community protocols commonly run 8-12 weeks with a 4-8 week break. Since natural humanin declines with age, some argue cycle-off periods matter less — but with no long-term human data, conservative cycling is the cautious default.
• Timing: morning dosing is generally preferred, particularly for metabolic goals; there is no strict food-timing requirement. Consistency (same time daily) is the main practical point.

Storage: keep unopened lyophilized vials frozen (-20°C) for long-term storage or refrigerated (2-8°C) for shorter periods; once reconstituted, refrigerate and use within about three to four weeks. Never freeze a reconstituted solution — ice crystals denature the peptide — and discard anything cloudy, discolored, or containing particulates. See the peptide storage guide for detail. None of this should be read as encouragement to self-administer an unapproved compound; it describes how the research doses are structured.

Straight talk: there are no published human safety trials for humanin and no long-term human toxicology. Any statement that it is "well tolerated" or has a "favorable safety profile" is an inference — drawn from humanin being an endogenous molecule the body already makes and from animal studies that did not report obvious toxicity — not something demonstrated in controlled human research. Treat the profile below as informed caution, not established safety.^[7]

Why the safety inference exists (and its limits)

• Endogenous molecule: humanin is produced naturally by human mitochondria, so administering more of a substance the body already handles is generally lower-risk than introducing a wholly foreign compound. That is a reasonable prior, not a guarantee.
• Cell-preserving, not growth-driving: humanin's action is anti-apoptotic — it keeps existing cells alive rather than stimulating them to divide, so it lacks the proliferation-driven concerns of growth-promoting compounds.
• Animal studies: rodent work at research doses has not reported obvious organ toxicity, but these were efficacy studies, not formal safety/toxicology trials, and none were in humans.

Reported effects (anecdotal / extrapolated, not from trials)

Effect	Frequency	Severity	Notes
Injection-site redness/irritation	Common	Mild	Transient; typical of any subcutaneous injection
Mild headache	Occasional	Mild	Usually in the first few days
Fatigue / drowsiness	Occasional	Mild	Possibly related to metabolic modulation
Mild GI discomfort	Rare	Mild	Occasional nausea, typically transient
Blood-glucose changes	Possible	Mild-moderate	Insulin-sensitizing effect may matter for diabetics on medication

These come from user reports and extrapolation, not from controlled data. The honest framing is that the human side-effect profile is simply not characterized.

Blood glucose — the one worth watching

Because humanin improved insulin sensitivity in rats,^[3] a theoretical concern is that it could lower blood glucose. For anyone on insulin or a sulfonylurea, an additive glucose-lowering effect could raise hypoglycemia risk, so glucose monitoring would be sensible. This is inference from rodent metabolic data, not a documented human interaction — but it is the most plausible practical caution. If stacking with MOTS-c, which also affects glucose handling, the theoretical effect could compound.

Theoretical concern: anti-apoptosis and cancer

Humanin's core mechanism is blocking programmed cell death. That raises a fair question: could sustained anti-apoptotic signaling help existing cancer cells evade the death the body would otherwise impose on them? There is no evidence that humanin causes cancer — it does not drive cell proliferation, and higher natural humanin in healthy people tracks with better, not worse, outcomes. But the theoretical concern is enough that anyone with active cancer, a recent cancer history, or a known genetic cancer predisposition should avoid exogenous humanin until this is specifically studied.

Who should avoid it, and unknowns

• Active or recent cancer: avoid, per the anti-apoptosis concern above.
• Pregnancy and breastfeeding: no reproductive-safety data — avoid.
• Diabetics on glucose-lowering drugs: monitor blood glucose; medication adjustment may be needed.
• Long-term use: no study has evaluated exogenous humanin beyond a few months. Whether chronic dosing downregulates the body's own production, or has cumulative effects, is unknown. Conservative cycling is the cautious response to that ignorance.

For broader context, see Are Peptides Safe? and Peptide Side Effects.

Why this section matters: humanin is an unregulated research compound, so purity and even identity vary widely between suppliers — and remember that most "humanin" on the market is actually the HNG analog. For an unproven peptide, contamination and mislabeling are arguably a bigger practical risk than the peptide itself. Learning to read a Certificate of Analysis (COA) is the single most useful skill here.

What a credible product should show

• Third-party COA: independent HPLC purity testing (look for ≥98%) plus mass-spectrometry identity confirming the expected molecular weight — and, critically, confirming whether it is native humanin or HNG.
• Batch-specific results: the COA should reference the exact lot you are buying, not a generic sample.
• Endotoxin testing (LAL): important for anything intended to be injected.
• Proper form and packaging: lyophilized powder in a sealed, light-protected vial.

Red flags

• No COA, or a COA from the seller rather than an independent lab
• No clear statement of whether the product is native humanin or HNG (a 1,000-fold potency difference)
• Pre-mixed "ready to use" liquid (shorter shelf life, contamination risk)
• Prices far below the market, or explicit human-use / medical claims (a sign of a non-compliant vendor)

Legal and regulatory status (2026)

• Not FDA-approved for any indication, in any country.
• No completed human safety trial: humanin has no finished Phase 1 study and no FDA drug approval.
• No compounding pathway: it holds no compounding or bulk-substance status, so there is no legal route for human therapeutic use in the U.S. Products sold online are unregulated research chemicals.

For the complete legal picture, read Are Peptides Legal?

Humanin's closest relative is MOTS-c, the other well-characterized mitochondrial-derived peptide. They are cousins — both encoded in mitochondrial DNA — but they do different jobs, which is why they are discussed together rather than as substitutes. This comparison contrasts mechanisms and the animal literature; there are no head-to-head human trials.

Feature	Humanin (HNG)	MOTS-c
Encoded in	16S rRNA gene (mtDNA)	12S rRNA gene (mtDNA)
Size	24 amino acids	16 amino acids
Primary mechanism	Anti-apoptotic (Bax binding); metabolic via hypothalamic STAT3	AMPK activation, metabolic regulation
Main studied uses	Cytoprotection, neuroprotection, insulin sensitivity	Exercise-mimetic, fat metabolism, glucose regulation
Evidence level	Preclinical; human data correlational only	Preclinical, with a separate emerging human research base

The characterization of MOTS-c as an AMPK-driven metabolic peptide that reduced diet-induced obesity and reversed age-dependent insulin resistance in mice comes from Lee and colleagues.^[6] Key insight: humanin leans toward keeping cells alive, while MOTS-c leans toward optimizing metabolism in living cells — complementary angles on mitochondrial aging rather than competing options. See the anti-aging peptides guide and the longevity stack for how they are combined.